Management of DAAs Failure

More documents

Recommendations

Info

All DAAs Can Select Resistant Variants Ala156 Arg155 Asp168 Val36 Thr54 Pawlotsky JM. Ther Adv Gastroenterol 2009;2:205–219; Donaldson et al., Hepatology 2015;61(1):56-65; Lam et al., Antimicrob Agents Chemother 2012;56(6):3359-68.
Multiple factors can affect the emergence of resistance variants, particularly: 1. The overall potency 2. Barrier to resistance of the combination regimen
Page 2 and 3: Management of DAAs Failure Prof. Ga
Page 4 and 5: • HCV is an enveloped, positive-s
Page 6 and 7: Antiviral Resistance • Each patie
Page 10 and 11: Barrier to Resistance Low-barrier d
Page 13: NS5B RAV(S) • Sofosbuvir has a hi
Page 16 and 17: Protease inhibitor-Resistant Viruse
Page 18 and 19: SVR12 (%) 24 Wks of LDV/SOF Retreat
Page 20 and 21: DAA Treatment Failure •Relapse or
Page 22 and 23: Treatment recommendations for retre
Page 24 and 25: A- Retreatment of patients with pre
Page 26 and 27: A- Retreatment of patients with pre
Page 28 and 29: Abstract ID: 849 Author: Ng T. et a
Page 30 and 31: Summary • Treatment-emergent RAV(

Management of DAAs Failure

Create successful ePaper yourself

Delete template?

Save as template?